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CONCLUSIONS: The new treatment guidelines were
implemented on more patients by year 2000. More males
were found to be on appropriate therapy than females.
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OBJECTIVES: Randomized clinical trials (RCTs) are the
gold standard for determining efﬁcacy of pharmaceutical
treatments, but ﬁndings from RCTs are often difﬁcult 
to translate into real-world (non-randomized) environ-
ments. This observational registry was designed to iden-
tify real-world outcomes among asthma patients receiving
various treatments for asthma. The registry protocol mir-
rored a previous RCT and was designed to provide con-
ﬁrmatory evidence for generalizability of prior research
ﬁndings. METHODS: Four hundred eighty-four physi-
cians from 13 states, including the west, central, north-
eastern, southeastern and midwestern areas of the U.S.,
were recruited and trained in registry procedures. Patients
were eligible if they were 15 years or older and required
a change in asthma control therapy as determined by their
physician during a regularly scheduled ofﬁce visit. No
recruitment was allowed to protect the observational
status of the registry. Asthma Control Questionnaire
(ACQ), Asthma Quality of Life Questionnaire (AQLQ),
medication satisfaction, and productivity end point data
have been obtained from baseline and will be obtained
from 1-month, 3-month, 6-month and 1-year surveys.
Utilization and cost data for inpatient, outpatient, emer-
gency room, and prescriptions will be obtained from the
individual’s health insurance claims data. RESULTS:
Eighty-one percent of physicians were general internists,
and 19% were allergists or pulmonologists. Sixty-seven
percent of all physicians had no previous research expe-
rience. Over 1400 patients entered the registry during the
enrollment period (01/2002–12/2002). Baseline charac-
teristics were well balanced across the four cohorts
despite lack of randomization. Analysis of baseline self-
reported ACQ and AQLQ individual questions identiﬁed
no statistically signiﬁcant differences between cohorts.
Follow-up survey results will be reported in future analy-
ses. CONCLUSIONS: Non randomized registry studies
can complement RCTs by providing an ample well bal-
anced sample size that is representative of real-word prac-
tice and makes available rapid feedback on clinical and
economic outcomes.
PRP3
CLINICAL EFFECTIVENESS OF BUDESONIDE
AND FORMOTEROL IN A SINGLE INHALER IN
PATIENTS WITH ASTHMA—AN AUDIT IN UK
GENERAL PRACTICE
Emmas CE1, Beaumont SD2
1AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom;
2AstraZeneca UK, Luton, Bedfordshire, United Kingdom
OBJECTIVES: Randomised controlled clinical trials
demonstrate how well treatments work under ideal con-
ditions (clinical efﬁcacy). However, once efﬁcacy has been
established there is a need to show how well treatment
work in the less ideal conditions of normal clinical prac-
tice (clinical effectiveness). This study is the ﬁrst to
demonstrate the clinical effectiveness of budesonide/for-
moterol in a single inhaler in the treatment of asthma in
UK general practice. METHODS: Patients with inade-
quately controlled asthma were identiﬁed following a
review of their patient notes and a consultation with a
clinical nurse specialist using criteria agreed with the
general practitioner. These patients were referred to the
doctor for a treatment review and a subsequent assess-
ment at six months. RESULTS: As a result of the review
119 patients, previously treated with ≥200mcg inhaled
corticosteroid daily, received budesonide/formoterol
(80/4.5mcg or 160/4.5mcg 1–2 puffs twice daily) in a
single inhaler for the ﬁrst time. Improvements were
observed in all measures of health outcomes. There was
a signiﬁcant increase in the mean peak expiratory ﬂow
between initial (415L/min) and 6 month (447L/min)
assessments (p < 0.0001). Patients reported a greater pro-
portion of symptom-free days (p < 0.0001) fewer episodes
of symptoms in the day (p < 0.0001) and at night (p <
0.0001). They reported a reduced use of reliever medica-
tion (p < 0.0001) and a reduction of exercise induced
asthma (p < 0.0001). There was a signiﬁcant decrease in
routine asthma-related primary care consultations (p <
0.0005) and fewer emergency GP visits (p < 0.001).
Patients understood their treatment better (p < 0.0001),
were concerned about their asthma for less of the time 
(p < 0.0001), and 98% of patients felt they had beneﬁted
from taking part in the programme of which this change
in therapy was a part. CONCLUSIONS: In this group of
asthmatic patients, inadequately controlled on ≥200mcg
inhaled corticosteroid daily, budesonide/formoterol in a
single inhaler provided signiﬁcant improvements, which
demonstrate superior clinical effectiveness.
